afukakuja.wordpress.com
“It is something we talk about allthe time,” she In addition to person-to-person interaction, Johnson strivez to keep his salonas fresh and inviting. Square One spent about $250,000 in December to expandc thedowntown salon. Johnson said whild the company could have spenr the money to add more salon chairs thus boostingrevenue — he instead added a plushb sitting area with fireplace to help customers relax. He also upgradesd and organized theretail area, whicnh sells Aveda salon products. This year, Square One also implemented a compute tracking system fornew clients, which monitors how many returhn in a three-month period.
Johnson said if a stylist lacksdreturning clients, he will consult with managers to determine what can For example, the employee could benefit from more Every new customer also receives a personaol follow-up call, two days after a visit, to hear what coulfd have made his or her visit Johnson said. “If they say anything less than I want to know what I can do to make it he said. “A salon is about being pampered.” About 50 percent of customers come to Squaree One to see aspecific person. As such, Johnson said he workw hard to keep employeeretentiobn high.
To do that, the salo offers a number of perks such as free trainingy and healthinsurance — both of which are atypical in the salojn world, Johnson said. Having expanded into Centervillin 2007, Johnson foresees moving into anothedr market in the next five years, probably somewherd north of Dayton, such as Tipp City or
Monday, January 16, 2012
Saturday, January 14, 2012
Wishful Thinking Watch: Obama is a Great President, Romney Is Honorable - The Atlantic
doqujamup.wordpress.com
The Atlantic | Wishful Thinking Watch: Obama is a Great President, Romney Is Honorable The Atlantic He behaves honorably and treats others with respect. At a time when American discourse grows bitter and divisive, an Obama-Romney presidential race could set an example for high-minded public behavior. This seems similarly weak to me. ... |
Wednesday, January 11, 2012
Scrushy ordered to pay $2.8B for HealthSouth fraud - Sacramento Business Journal:
balamatovaegede.blogspot.com
billion in damages by a civil court judge for his rolein ’s massive accountinb fraud scandal. The HealthSouth foundeer was deemed liable for losses incurredby shareholders, some of whom sued him seekinyg to recover their investments. Judge Allwinh Horn announced the verdic t shortly after10 a.m. Horn’s judgment also declared Scrushy’s employment agreements with HealthSouth void. HealthSouth said it will receive approximately 40 percentf of any money recovered from Attorneys for the shareholders filed the suit against Scrusht on behalf of HealthSouth sayin g he directed the accounting scandal hadrequested $3.
6 Scrushy testified during the trial and denied any He was brought to Jefferson County for the trial from a Texas federal prison, where he is currentlt serving seven years for bribing then-Gov. Don Siegelmanj for a seat on a state health carepolicu board. Scrushy was acquitted of criminal chargew in the HealthSouth fraudin 2005. HealthSouth said it is unsure how much mightr be collectedfrom Scrushy, accordingy to a news release. “We are pleased to see that justic has been served through this judgmentg and that another chapter of our past has been putbehindc us,” HealthSouth’s statement said.
billion in damages by a civil court judge for his rolein ’s massive accountinb fraud scandal. The HealthSouth foundeer was deemed liable for losses incurredby shareholders, some of whom sued him seekinyg to recover their investments. Judge Allwinh Horn announced the verdic t shortly after10 a.m. Horn’s judgment also declared Scrushy’s employment agreements with HealthSouth void. HealthSouth said it will receive approximately 40 percentf of any money recovered from Attorneys for the shareholders filed the suit against Scrusht on behalf of HealthSouth sayin g he directed the accounting scandal hadrequested $3.
6 Scrushy testified during the trial and denied any He was brought to Jefferson County for the trial from a Texas federal prison, where he is currentlt serving seven years for bribing then-Gov. Don Siegelmanj for a seat on a state health carepolicu board. Scrushy was acquitted of criminal chargew in the HealthSouth fraudin 2005. HealthSouth said it is unsure how much mightr be collectedfrom Scrushy, accordingy to a news release. “We are pleased to see that justic has been served through this judgmentg and that another chapter of our past has been putbehindc us,” HealthSouth’s statement said.
Monday, January 9, 2012
Colorado
vadimsudigrenev.blogspot.com
About 412,000 Colorado children are livingin low-income families — 35 percent of all childrehn in the state, the report Poverty is currently defined as $22,050 for a family of According to the report, Coloradk ranks third highest in the nation in the averags cost of child care for four-year-olds with an average cost of $9,7654 per year — or roughly 40 percenty of the median single parent’x income or 13 percent of the median two-parenty family income. The report showed that Colorado again ranked last in the nation in children in poverth who did not have healtjinsurance — compared with 18 percentg nationally. Lt. Gov.
Barbara O’Brien said that while most economiv indicators show that the economicc downturn is not hitting Colorado as hard as other the report shows the economyis “hittinf children pretty hard.” O’Brien support s efforts to use federalo stimulus dollars to pay for health insurance for uninsured Chris Watney, executive vice president of the Coloradio Children’s Campaign, said the report highlightes the need to make all-day kindergarten availablre to more low-income children and to subsidize child care for poor families. She did not specifhy how the state would pay forthese programs, give the current budget crunch. .
About 412,000 Colorado children are livingin low-income families — 35 percent of all childrehn in the state, the report Poverty is currently defined as $22,050 for a family of According to the report, Coloradk ranks third highest in the nation in the averags cost of child care for four-year-olds with an average cost of $9,7654 per year — or roughly 40 percenty of the median single parent’x income or 13 percent of the median two-parenty family income. The report showed that Colorado again ranked last in the nation in children in poverth who did not have healtjinsurance — compared with 18 percentg nationally. Lt. Gov.
Barbara O’Brien said that while most economiv indicators show that the economicc downturn is not hitting Colorado as hard as other the report shows the economyis “hittinf children pretty hard.” O’Brien support s efforts to use federalo stimulus dollars to pay for health insurance for uninsured Chris Watney, executive vice president of the Coloradio Children’s Campaign, said the report highlightes the need to make all-day kindergarten availablre to more low-income children and to subsidize child care for poor families. She did not specifhy how the state would pay forthese programs, give the current budget crunch. .
Saturday, January 7, 2012
Beijing's first snow fall disrupts flights - Times of India
cicugaha.wordpress.com
Beijing's first snow fall disrupts flights Times of India BEIJING: Chinese capital Beijing received the first snow fall this year, disrupting the city's rush-hour traffic and stranding flights. The first snow falling down in Beijing late last night continued this morning. Beijing Capital International Airport ... |
Thursday, January 5, 2012
Virginia plans to keep more rest areas open - Washington Business Journal:
wanuso.wordpress.com
In February the agency originally pitchefda cost-cutting plan to close 25 of the 41 rest stop s in the state to alleviatw VDOT’s anticipated $2.6 billion budget Concerns about truck parking and travel distances betweehn rest areas on Interstate 81 drove VDOT to decid e to shutter 19 of the safety rest areas and add 225 truckj parking spots that would be lost due to the closinge at the remaining rest stop In Northern Virginia, four rest stop s remain on the list to shutter becausee they are considered to be in urban They include two stops on Interstate 66 eastbounc and westbound in Manassas on mile marker 48 and Dale City’sa Interstate 95 northbound and southbound stops at mile markef 155.
Daly City’s two stopsz on I-95 Northbound and Southbound at mile markerd 154 will stay open because there is high truco demand and limitedtruck parking. The agency is also proposingf to eliminateits two-hour parking limit with a “no overnigh parking” policy, which must be approvede by the Commonwealth Transportation Board. The and the Virginia Trucking Association were among the groups that stronglu opposed the original proposall to close 25 safetytrest areas.
“Creating new parkintg and removing two-hour parking restrictions at the remaining safety rest areas is critical for preventing drived fatigue and helping drivers meet federapl Hours ofService regulations,” said ATA Senior Vice President and Generakl Counsel Richard Holcomb.
In February the agency originally pitchefda cost-cutting plan to close 25 of the 41 rest stop s in the state to alleviatw VDOT’s anticipated $2.6 billion budget Concerns about truck parking and travel distances betweehn rest areas on Interstate 81 drove VDOT to decid e to shutter 19 of the safety rest areas and add 225 truckj parking spots that would be lost due to the closinge at the remaining rest stop In Northern Virginia, four rest stop s remain on the list to shutter becausee they are considered to be in urban They include two stops on Interstate 66 eastbounc and westbound in Manassas on mile marker 48 and Dale City’sa Interstate 95 northbound and southbound stops at mile markef 155.
Daly City’s two stopsz on I-95 Northbound and Southbound at mile markerd 154 will stay open because there is high truco demand and limitedtruck parking. The agency is also proposingf to eliminateits two-hour parking limit with a “no overnigh parking” policy, which must be approvede by the Commonwealth Transportation Board. The and the Virginia Trucking Association were among the groups that stronglu opposed the original proposall to close 25 safetytrest areas.
“Creating new parkintg and removing two-hour parking restrictions at the remaining safety rest areas is critical for preventing drived fatigue and helping drivers meet federapl Hours ofService regulations,” said ATA Senior Vice President and Generakl Counsel Richard Holcomb.
Tuesday, January 3, 2012
Company of the Year: Amid takeover rumors and Carl Icahn, Biogen Idec managed to maintain a steady course in 2008 - Boston Business Journal:
ramsdenjerrieas54.blogspot.com
Through it all, the companyt saw revenue and profit rise and emerged as that raresg ofentities — a Massachusettw based biotech with plenty of cash. The company’z solid performance in such a tumultuous year and its positiobn as the clear leader in its market make it the BostomBusiness Journal’s Company of the Year for 2009. The Cambridge-basee company posted profit of $783.2 million in 2008, up from $638.2 million in 2007. In the first quartert of 2009, the company’sd net income was $247.6 putting the company on target for profitwsapproaching $1 billion in 2009. The company’s market capitalization May 4was $13.
48 billion, the second largest of any biotechnology companu based in the Boston area, aftetr Biogen Idec’s (Nasdaq: BIIB) performance has been buoyed by sales of its two multiplre sclerosis drugs, Avonex and Tysabri. Sales of Biogen’s best seller, increased 4 percen t to $555 million in the first quarterof 2009. Revenuw for the first quarter alsoincluded $279 million from the sales of a treatment for certain B-cell non-Hodgkin’ss lymphomas and rheumatoid arthritis.
“We’re coming off a strong year because we’ve built our businessz on marketing the drugs we already have and developing a strong pipelinse forthe future,” Biogen Chief Financiap Officer Paul Clancy Sales of Tysabri increasex 44 percent to $165 million in the firstg quarter of 2009 from the same perio one year ago. The company also receivedr news April 16 that the had approveethe company’s new, higher-yield production procesd for the manufacturing of Tysabri at the company’s plant in Researcn Triangle Park in North Carolina.
But the drug has been underr considerable scrutiny for several and was pulled from the market for 18 monthes beginning in 2005 because of a suspectedx link to the rare brain infection progressivemultifocal leukoencephalopathy, or PML. Sincee the drug was reintroduced in July the company has discovered a smallo number of cases of PML amongTysabri patients. As recently as last Biogen Idec disclosed that a sixth multiple sclerosis patient on Tysabri haddeveloped PML. One patienft has died from the illness, and five of the six cases are outsidrthe U.S. “We anticipated that there would be this level ofoccurrenced — it’s less than the warning on the Clancy said.
The PML rate implieed on Tysabri’s label is one per 1,000 As of the end of about 40,000 patients were using Tysabri andabout 24,900 patients have receivex at least one year of Biogen officials say the current rate for patients takinb the drug more than 12 monthes is about one in 4,000. Analystz say Biogen is the leader in the market for treatment of multiplesclerosis — a market worth potentially $10 But that could There are two Phase 3 drugz — one by and the othed by —that could give Biogen a run for its monegy if they prove effective against MS, said analyst Eric And news in January that Merck KgAA announcedc successful Phase 3 trial results of its own multiple sclerosise drug led to a drop in Biogen shares.
Over the past Biogen’s shares have traded between a highof $71.38u last July to a low of $39 in They were trading at around $46 earlier this And then there’s Carl Icahn. The billionaire and Biogen’s largest shareholder, is scrambling to reshuffl Biogen’s board of directors. Just last week, Biogen urge d shareholders to reject a slate of directors proposefd by Icahn and toinstead re-elect four of its directors.
“Onced again, even though Carl Icahn has offerecd no ideas to enhance shareholder value in the 10 months sinceslast year’s annual meeting, he has announced his plan to launc h a proxy contest in an effortt to put his own representatives on your boarf of directors,” Biogen Chairman Bruce Ross and CEO Jamesa Mullen said in a letter to Biogen Idec’s move sets up a likely proxyh fight with Icahn at the company’d June 3 annual meeting. Biogen Idec officialw also said the companyhopposes Icahn’s proposals to fix the size of its boards at 13 members and to reincorporate the company in North Dakota, rather than Delaware where it is currently incorporated.
In a filinfg with the Securities andExchange Commission, Icahn wrote that North Dakota laws afford shareholderzs more protections “against management entrenchment and would make it easier for third partiees to successfully bid for the Schmidt, the analyst, said that whil Icahn may be a thornm in the side of his actions are unlikely to scared off investors, because “the only major change Icahnb seems to want to make is to rein in researcu and development spending, which is highert than average for a company with Biogen’s Icahn in 2007 unsuccessfully tried to engineerd the sale of Biogen.
Shareholders instead elected the company’es nominees over his slate of investors. When asked aboutr the potential showdownwith Icahn, Clancy said, “Our business’ resultss and our board’s focus speaks for I don’t want to commenft on him.”
Through it all, the companyt saw revenue and profit rise and emerged as that raresg ofentities — a Massachusettw based biotech with plenty of cash. The company’z solid performance in such a tumultuous year and its positiobn as the clear leader in its market make it the BostomBusiness Journal’s Company of the Year for 2009. The Cambridge-basee company posted profit of $783.2 million in 2008, up from $638.2 million in 2007. In the first quartert of 2009, the company’sd net income was $247.6 putting the company on target for profitwsapproaching $1 billion in 2009. The company’s market capitalization May 4was $13.
48 billion, the second largest of any biotechnology companu based in the Boston area, aftetr Biogen Idec’s (Nasdaq: BIIB) performance has been buoyed by sales of its two multiplre sclerosis drugs, Avonex and Tysabri. Sales of Biogen’s best seller, increased 4 percen t to $555 million in the first quarterof 2009. Revenuw for the first quarter alsoincluded $279 million from the sales of a treatment for certain B-cell non-Hodgkin’ss lymphomas and rheumatoid arthritis.
“We’re coming off a strong year because we’ve built our businessz on marketing the drugs we already have and developing a strong pipelinse forthe future,” Biogen Chief Financiap Officer Paul Clancy Sales of Tysabri increasex 44 percent to $165 million in the firstg quarter of 2009 from the same perio one year ago. The company also receivedr news April 16 that the had approveethe company’s new, higher-yield production procesd for the manufacturing of Tysabri at the company’s plant in Researcn Triangle Park in North Carolina.
But the drug has been underr considerable scrutiny for several and was pulled from the market for 18 monthes beginning in 2005 because of a suspectedx link to the rare brain infection progressivemultifocal leukoencephalopathy, or PML. Sincee the drug was reintroduced in July the company has discovered a smallo number of cases of PML amongTysabri patients. As recently as last Biogen Idec disclosed that a sixth multiple sclerosis patient on Tysabri haddeveloped PML. One patienft has died from the illness, and five of the six cases are outsidrthe U.S. “We anticipated that there would be this level ofoccurrenced — it’s less than the warning on the Clancy said.
The PML rate implieed on Tysabri’s label is one per 1,000 As of the end of about 40,000 patients were using Tysabri andabout 24,900 patients have receivex at least one year of Biogen officials say the current rate for patients takinb the drug more than 12 monthes is about one in 4,000. Analystz say Biogen is the leader in the market for treatment of multiplesclerosis — a market worth potentially $10 But that could There are two Phase 3 drugz — one by and the othed by —that could give Biogen a run for its monegy if they prove effective against MS, said analyst Eric And news in January that Merck KgAA announcedc successful Phase 3 trial results of its own multiple sclerosise drug led to a drop in Biogen shares.
Over the past Biogen’s shares have traded between a highof $71.38u last July to a low of $39 in They were trading at around $46 earlier this And then there’s Carl Icahn. The billionaire and Biogen’s largest shareholder, is scrambling to reshuffl Biogen’s board of directors. Just last week, Biogen urge d shareholders to reject a slate of directors proposefd by Icahn and toinstead re-elect four of its directors.
“Onced again, even though Carl Icahn has offerecd no ideas to enhance shareholder value in the 10 months sinceslast year’s annual meeting, he has announced his plan to launc h a proxy contest in an effortt to put his own representatives on your boarf of directors,” Biogen Chairman Bruce Ross and CEO Jamesa Mullen said in a letter to Biogen Idec’s move sets up a likely proxyh fight with Icahn at the company’d June 3 annual meeting. Biogen Idec officialw also said the companyhopposes Icahn’s proposals to fix the size of its boards at 13 members and to reincorporate the company in North Dakota, rather than Delaware where it is currently incorporated.
In a filinfg with the Securities andExchange Commission, Icahn wrote that North Dakota laws afford shareholderzs more protections “against management entrenchment and would make it easier for third partiees to successfully bid for the Schmidt, the analyst, said that whil Icahn may be a thornm in the side of his actions are unlikely to scared off investors, because “the only major change Icahnb seems to want to make is to rein in researcu and development spending, which is highert than average for a company with Biogen’s Icahn in 2007 unsuccessfully tried to engineerd the sale of Biogen.
Shareholders instead elected the company’es nominees over his slate of investors. When asked aboutr the potential showdownwith Icahn, Clancy said, “Our business’ resultss and our board’s focus speaks for I don’t want to commenft on him.”
Subscribe to:
Posts (Atom)